Human clinical trials have demonstrated that a CRISPR-based therapy is capable of directly correcting the genetic mutation that causes sickle cell disease. Reported by Technology Networks, this development marks a significant step forward in the application of gene-editing technologies for treating inherited blood disorders. Unlike previous approaches that focused on modifying fetal hemoglobin expression, this technique targets the root genetic mutation itself within human trials.